AGEs–RAGE axis mediates myocardial fibrosis via activation of cardiac fibroblasts induced by autophagy in heart failure

What is the central question of this study? Does the advanced glycation end products (AGEs)–receptor for advanced glycation end products (RAGE) axis mediate myocardial fibrosis in heart failure? What is the main finding and its importance? The AGEs–RAGE axis is involved in the pathogenesis of myocardial fibrosis through activation of cardiac fibroblasts induced by autophagy in heart failure. By suppression of cardiac fibroblast activation, inhibition of the AGEs–RAGE axis attenuates cardiac dysfunction and myocardial fibrosis in mice with transverse aortic constriction.

[1]  C. Brooks,et al.  Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[2]  N. Nieto,et al.  Aminoguanidine reduces diabetes-associated cardiac fibrosis. , 2019, Experimental and therapeutic medicine.

[3]  J. González-Juanatey,et al.  The different roles for the advanced glycation end products axis in heart failure and acute coronary syndrome settings. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[4]  Kuan-Cheng Chang,et al.  Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model , 2019, BMC Nephrology.

[5]  J. Esplugues,et al.  Autophagy Stimulation as a Potential Strategy Against Intestinal Fibrosis , 2019, Cells.

[6]  N. Frangogiannis.  Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. , 2019, Molecular aspects of medicine.

[7]  Zheng Zhou,et al.  Inhibiting Receptor of Advanced Glycation End Products Attenuates Pressure Overload-Induced Cardiac Dysfunction by Preventing Excessive Autophagy , 2018, Front. Physiol..

[8]  J. Molkentin,et al.  Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure , 2018, Circulation.

[9]  Q. Tang,et al.  Cardiac fibrosis: new insights into the pathogenesis , 2018, International journal of biological sciences.

[10]  J. Peart,et al.  Biomarkers for the identification of cardiac fibroblast and myofibroblast cells , 2018, Heart Failure Reviews.

[11]  J. Butler,et al.  Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives. , 2018, Journal of the American College of Cardiology.

[12]  Zhimin Zha,et al.  Pitavastatin attenuates AGEs-induced mitophagy via inhibition of ROS generation in the mitochondria of cardiomyocytes , 2018, Journal of biomedical research.

[13]  J. Mialet-Perez,et al.  Autophagy in health and disease: focus on the cardiovascular system. , 2017, Essays in biochemistry.

[14]  V. Bito,et al.  Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs , 2017, Amino Acids.

[15]  C. Sergi,et al.  Autophagy-Inflammasome Interplay in Heart Failure: A Systematic Review on Basics, Pathways, and Therapeutic Perspectives. , 2017, Annals of clinical and laboratory science.

[16]  T. Quertermous,et al.  Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment , 2016, Nature Communications.

[17]  Wei Zhang,et al.  Blockade of receptor for advanced glycation end products protects against systolic overload-induced heart failure after transverse aortic constriction in mice. , 2016, European journal of pharmacology.

[18]  T. Minamino,et al.  Physiological and pathological cardiac hypertrophy. , 2016, Journal of molecular and cellular cardiology.

[19]  Lei Wang,et al.  Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions , 2016, Glycoconjugate Journal.

[20]  K. Otsu.  "Autophagy in the Heart". , 2016, Journal of molecular and cellular cardiology.

[21]  B. Hinz,et al.  Mechanical control of cardiac myofibroblasts. , 2016, Journal of molecular and cellular cardiology.

[22]  T. Quertermous,et al.  Targeting LOXL 2 for cardiac interstitial fibrosis and heart failure treatment , 2016 .

[23]  D. Grundy.  Principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology , 2015, Experimental physiology.

[24]  David Grundy,et al.  Principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology , 2015, The Journal of physiology.

[25]  Hui-hua Li,et al.  A soluble receptor for advanced glycation end-products inhibits myocardial apoptosis induced by ischemia/reperfusion via the JAK2/STAT3 pathway , 2015, Apoptosis.

[26]  Y. Tham,et al.  Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets , 2015, Archives of Toxicology.

[27]  J. Stewart,et al.  Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart. , 2014, World journal of diabetes.

[28]  M. Hébert,et al.  Autophagy fosters myofibroblast differentiation through MTORC2 activation and downstream upregulation of CTGF , 2014, Autophagy.

[29]  A. Giatromanolaki,et al.  Neutrophil extracellular traps promote differentiation and function of fibroblasts , 2014, The Journal of pathology.

[30]  S. Yamagishi.  Advanced Glycation End-Products , 2013 .

[31]  A. Jenkins,et al.  Diastolic Dysfunction of Aging Is Independent of Myocardial Structure but Associated with Plasma Advanced Glycation End-Product Levels , 2012, PloS one.

[32]  M. Mamas,et al.  Role of advanced glycation end products in cardiovascular disease. , 2012, World journal of cardiology.

[33]  R. Ramasamy,et al.  Receptor for Advanced Glycation End Products (RAGE) and Implications for the Pathophysiology of Heart Failure , 2012, Current Heart Failure Reports.

[34]  S. Raposeiras-Roubín,et al.  Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels , 2010, European journal of heart failure.

[35]  H. Hirase,et al.  Deletion of RAGE Causes Hyperactivity and Increased Sensitivity to Auditory Stimuli in Mice , 2009, PloS one.

[36]  M. Cheitlin.  High Serum Level of Pentosidine, an Advanced Glycation End Product (AGE), is a Risk Factor of Patients with Heart Failure , 2008 .

[37]  Kheya Sengupta,et al.  Fibroblast adaptation and stiffness matching to soft elastic substrates. , 2007, Biophysical journal.

[38]  I. Kubota,et al.  High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure. , 2007, Journal of cardiac failure.

[39]  Ichiro Manabe,et al.  [Cardiac fibrosis]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[40]  M. Maurer,et al.  Pathophysiology of Heart Failure , 2007 .

[41]  P. Janmey,et al.  Biomechanics and Mechanotransduction in Cells and Tissues Cell type-specific response to growth on soft materials , 2005 .

[42]  M. Hori,et al.  Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation. , 2002, American journal of physiology. Heart and circulatory physiology.

[43]  Gordon Ross,et al.  Pathophysiology of the heart , 1982 .